FOLD Amicus Therapeutics Inc

Price (delayed)

$11

Market cap

$2.93B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.96

Enterprise value

$3.2B

Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics ...

Highlights
FOLD's revenue is up by 24% year-on-year and by 6% since the previous quarter
Amicus Therapeutics's gross profit has increased by 24% YoY and by 6% QoQ
Amicus Therapeutics's quick ratio has increased by 18% YoY but it has decreased by 17% from the previous quarter
FOLD's debt has surged by 118% year-on-year
The equity has contracted by 41% YoY and by 15% from the previous quarter

Key stats

What are the main financial stats of FOLD
Market
Shares outstanding
266.56M
Market cap
$2.93B
Enterprise value
$3.2B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
13.68
Price to sales (P/S)
10.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.35
Earnings
Revenue
$281.82M
EBIT
-$216.46M
EBITDA
-$208.24M
Free cash flow
-$202.69M
Per share
EPS
-$0.96
Free cash flow per share
-$0.76
Book value per share
$0.8
Revenue per share
$1.06
TBVPS
$2.21
Balance sheet
Total assets
$786.89M
Total liabilities
$572.98M
Debt
$441.74M
Equity
$213.91M
Working capital
$368.51M
Liquidity
Debt to equity
2.07
Current ratio
4.29
Quick ratio
3.86
Net debt/EBITDA
-1.27
Margins
EBITDA margin
-73.9%
Gross margin
88.4%
Net margin
-89.5%
Operating margin
-73.3%
Efficiency
Return on assets
-29.8%
Return on equity
-94.2%
Return on invested capital
-27.3%
Return on capital employed
-32.1%
Return on sales
-76.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FOLD stock price

How has the Amicus Therapeutics stock price performed over time
Intraday
-0.72%
1 week
0.64%
1 month
4.07%
1 year
-20.98%
YTD
-52.36%
QTD
14.11%

Financial performance

How have Amicus Therapeutics's revenue and profit performed over time
Revenue
$281.82M
Gross profit
$249.09M
Operating income
-$206.5M
Net income
-$252.3M
Gross margin
88.4%
Net margin
-89.5%
The operating margin rose by 39% YoY and by 11% QoQ
FOLD's net margin is up by 31% year-on-year and by 6% since the previous quarter
Amicus Therapeutics's operating income has increased by 24% YoY and by 6% QoQ
FOLD's revenue is up by 24% year-on-year and by 6% since the previous quarter

Growth

What is Amicus Therapeutics's growth rate over time

Valuation

What is Amicus Therapeutics stock price valuation
P/E
N/A
P/B
13.68
P/S
10.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.35
The EPS has grown by 16% YoY
The P/B is 93% above the 5-year quarterly average of 7.1
The equity has contracted by 41% YoY and by 15% from the previous quarter
FOLD's price to sales (P/S) is 84% lower than its 5-year quarterly average of 64.6 and 27% lower than its last 4 quarters average of 14.2
FOLD's revenue is up by 24% year-on-year and by 6% since the previous quarter

Efficiency

How efficient is Amicus Therapeutics business performance
The ROIC has grown by 46% YoY and by 13% from the previous quarter
Amicus Therapeutics's return on equity has decreased by 44% YoY and by 13% QoQ
The ROS has grown by 36% YoY and by 8% from the previous quarter
FOLD's ROA is up by 19% YoY and by 2.9% from the previous quarter

Dividends

What is FOLD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FOLD.

Financial health

How did Amicus Therapeutics financials performed over time
FOLD's total assets is 37% greater than its total liabilities
The total liabilities has soared by 68% YoY and by 2.5% QoQ
FOLD's current ratio is up by 21% year-on-year but it is down by 15% since the previous quarter
FOLD's debt is 107% greater than its equity
FOLD's debt has surged by 118% year-on-year
The equity has contracted by 41% YoY and by 15% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.